85 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
31
Helixconstraints and amino acid substitution in GLP-1 increase cAMP and insulin secretion but not beta-arrestin 2 signaling.
The University of Queensland
6
Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione Core.
Vanderbilt University
85
Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance.
Ferring Research Institute
13
A new GLP-1 analogue with prolonged glucose-lowering activity in vivo via backbone-based modification at the N-terminus.
Peking University
29
Cyclic alpha-conotoxin peptidomimetic chimeras as potent GLP-1R agonists.
The University of Queensland
46
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
Novo Nordisk
18
Short Hydrophobic Peptides with Cyclic Constraints Are Potent Glucagon-like Peptide-1 Receptor (GLP-1R) Agonists.
University of Queensland
22
Discovery of furan-2-carbohydrazides as orally active glucagon receptor antagonists.
Dainippon Sumitomo Pharma
7
Discovery of (S)-2-cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM).
Vanderbilt University School of Medicine
78
The discovery of N-((2H-tetrazol-5-yl)methyl)-4-((R)-1-((5r,8R)-8-(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822): a potent and selective glucagon receptor antagonist.
Merck Research Laboratories
8
A general method for making peptide therapeutics resistant to serine protease degradation: application to dipeptidyl peptidase IV substrates.
Tufts University
1
The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus.
Pfizer
31
Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-ß-alanine (MK-0893) for the treatment of type II diabetes.
Merck Research Laboratories
45
Cyclobutane derivatives as novel nonpeptidic small molecule agonists of glucagon-like peptide-1 receptor.
The National Center For Drug Screening
31
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.
Indiana University
23
Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity.
Bristol Myers Squibb
19
A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity.
Pfizer
27
Discovery of N-aryl-2-acylindole human glucagon receptor antagonists.
Merck Research Laboratories
33
Discovery of cyclic guanidines as potent, orally active, human glucagon receptor antagonists.
Merck Research Laboratories
41
Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core.
Merck Research Laboratories
12
Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges.
University of Texas At Dallas
1
Identification of glycosylated exendin-4 analogue with prolonged blood glucose-lowering activity through glycosylation scanning substitution.
Shionogi
8
Preparation and structural, biochemical, and pharmaceutical characterizations of bile acid-modified long-acting exendin-4 derivatives.
Sungkyunkwan University
20
Search for alpha-helical propensity in the receptor-bound conformation of glucagon-like peptide-1.
University of Texas At Dallas
8
Influence of selective fluorination on the biological activity and proteolytic stability of glucagon-like peptide-1.
Tufts University
27
Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor.
Novo Nordisk
21
Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity.
Amgen
2
A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice.
National Center For Drug Screening
2
Discovery of Selenium-Containing Derivatives as Potent and Orally Bioavailable GLP-1R Agonists.
China Pharmaceutical University
5
Binding sites and design strategies for small molecule GLP-1R agonists.
China Pharmaceutical University
32
Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor.
Pfizer
9
6-Azaspiro[2.5]octanes as small molecule agonists of the human glucagon-like peptide-1 receptor.
Pfizer
6
Novel 2,5-Diazabicyclo[4.2.0]octanes as GLP-1 Receptor Modulators for Treating Type 2 Diabetes.
Smith, Gambrell & Russell
20
Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment.
Sichuan University
42
New beta-alanine derivatives are orally available glucagon receptor antagonists.
Novo Nordisk
12
A novel long-acting oxyntomodulin analogue eliminates diabetes and obesity in mice.
Beijing University of Chinese Medicine
18
Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists.
Affiliated Tumor Hospital of Guangxi Medical University
3
Discovery of V-0219: A Small-Molecule Positive Allosteric Modulator of the Glucagon-Like Peptide-1 Receptor toward Oral Treatment for "Diabesity".
Hospital Regional Universitario
6
Discovery of Insulin/GLP-1/Glucagon Triagonists for the Treatment of Diabetes and Obesity.
Merck
10
Peptide-based long-acting co-agonists of GLP-1 and cholecystokinin 1 receptors as novel anti-diabesity agents.
Jiangsu Normal University
32
Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists.
Merck Research Laboratories
22
Modifying a Hydroxyl Patch in Glucagon-like Peptide 1 Produces Biased Agonists with Unique Signaling Profiles.
The University of Queensland
14
Discovery of MK-1462: GLP-1 and Glucagon Receptor Dual Agonist for the Treatment of Obesity and Diabetes.
Merck
9
Synthesis and biological evaluation of glucagon-like peptide-1 analogs with the C-terminal helix 3 of albumin-binding domain 3.
China State Institute of Pharmaceutical Industry
5
Discovery of an Orally Efficacious Positive Allosteric Modulator of the Glucagon-like Peptide-1 Receptor.
Lilly Research Laboratories
9
Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog.
Conjuchem
13
Design, synthesis and biological evaluation of double fatty chain-modified glucagon-like peptide-1 conjugates.
Fudan University School of Pharmacy
27
Optimization of Truncated Glucagon Peptides to Achieve Selective, High Potency, Full Antagonists.
Indiana University
17
Rational design and biological evaluation of gemfibrozil modified Xenopus GLP-1 derivatives as long-acting hypoglycemic agents.
Jiangnan University
10
Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis.
Syracuse University
15
Automated Design of Macrocycles for Therapeutic Applications: From Small Molecules to Peptides and Proteins.
Schrodinger
36
Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration.
Novo Nordisk
6
Novel lipid side chain modified exenatide analogs emerged prolonged glucoregulatory activity and potential body weight management properties.
China Pharmaceutical University
2
Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors.
Sosei Heptares
14
Natural dimers of coumarin, chalcones, and resveratrol and the link between structure and pharmacology.
Nagasaki International University
86
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
Shanghaitech University
4
Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R).
Sanofi-Aventis Deutschland
40
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Terns Pharmaceuticals
19
Design, synthesis, and biological activity of novel dicoumarol glucagon-like peptide 1 conjugates.
China Pharmaceutical University
8
Novel fatty acid chain modified GLP-1 derivatives with prolonged in vivo glucose-lowering ability and balanced glucoregulatory activity.
China Pharmaceutical University
16
Optimization of peptide-based polyagonists for treatment of diabetes and obesity.
Novo Nordisk Research Center Indianapolis
28
A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects.
China Pharmaceutical University
16
Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations.
Sanofi-Aventis Deutschland
22
Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists.
Sanofi-Aventis Deutschland
11
Peptide Half-Life Extension: Divalent, Small-Molecule Albumin Interactions Direct the Systemic Properties of Glucagon-Like Peptide 1 (GLP-1) Analogues.
University of Copenhagen
283
PYRIDONE AND PYRIMIDINONE INHIBITORS OF HEMATOPOIETIC PROGENITOR KINASE 1
Curadev Pharma
790
17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof
Enanta Pharmaceuticals
81
AROMATIC HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
Shanghai Institute of Materia Medica
47
AMYLOID PROTEIN-SELECTIVE BACE INHIBITORS (ASBIs) FOR ALZHEIMER'S DISEASE
University of California
19
3-phenyl-isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors
Nerviano Medical Sciences
15
Synthesis and anticholinesterase activity of new substituted benzo[d]oxazole-based derivatives.
Shahid Bahonar University of Kerman